PONTE VEDRA, Fla., Dec. 11, 2025 -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of current anticoagulation therapy, today announced the acquisition...

Researchers, university tech transfer offices, pharmaceutical companies, and disease-focused philanthropic organizations often face a challenge in translating academic research projects into viable licensing candidates or start-up companies. Pappas Translational Medicine works hands-on with our partners to help identify, catalyze and manage those projects that have the best chance to become market-ready.
We target life science technologies and platforms with high potential to reach private-sector transaction-enabling milestones—with the goal of expanding the pipeline of high quality translational medicine programs.
© 2025 Pappas Capital, LLC. ALL RIGHTS RESERVED.